Financial Results Schedules, Approvals, Appointments, Product Launches, and Stock Movements - Analyst Notes on Allergan, Accuray, Cerus, Galena Biopharma, and ZELTIQ Aesthetic
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, April 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Accuray Incorporated (NASDAQ: ARAY), Cerus Corporation (NASDAQ: CERS), Galena Biopharma, Inc. (NASDAQ: GALE), and ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Allergan Inc. Analyst Notes
On April 4, 2014, Allergan Inc. (Allergan) announced that David Pyott, Chairman of the Board and CEO, and Jeff Edwards, Executive Vice President, Finance and Business Development, CFO, will discuss the Company's Q1 2014 results on May 7, 2014. According to the Company, a live webcast of the call can be accessed through the Company website starting at 8:00 a.m. PT, and a replay of the discussion will also be available at the website shortly after the call for one week. The full analyst notes on Allergan Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/AGN/report.pdf
--
Accuray Incorporated Analyst Notes
On March 27, 2014, Accuray Incorporated (Accuray) announced that it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the CyberKnife® M6™ System to treat radiation therapy patients. According to Accuray, the system will be marketed as the "CyberKnife M6 Series" in Japan, offering the widest range of motion and highest-precision conformal delivery available and enabling patients to lie comfortably and breathe freely while receiving precise, high dose radiation therapy in a relatively short number of treatments, reducing side effects and preserving quality of life. Additionally, the Company stated that the CyberKnife System enables physicians to precisely maximize dose, minimize side effects and maximize patient comfort. Juki Hozumi, President and General Manager of Japan at Accuray, commented, "At Accuray, we understand the priority that our customers place on advanced medical technology and patient comfort. We are committed to excellence in service, support and education that will enable our customers to optimize their use of our leading-edge tumor treatments long-term." The full analyst notes on Accuray Incorporated are available to download free of charge at:
http://www.AnalystsReview.com/04092014/ARAY/report.pdf
--
Cerus Corporation Analyst Notes
On March 25, 2014, Cerus Corporation (Cerus) announced that Dr. Frank Witney, President and CEO of Affymetrix, has joined the Company's Board of Directors and the Compensation Committee. According to the Company, Dr. Witney will fill the board seat vacated by B. J. Cassin upon his retirement from the board last December 31, 2013. Commenting on the appointment, Obi Greenman, President and CEO of Cerus, stated, "On behalf of the management team and board of directors, I am delighted to welcome Dr. Witney to Cerus. His extensive commercial experience in the life science space will serve as a valuable asset to the Company as we prepare for a possible launch of our INTERCEPT platelet and plasma products in the U.S." The full analyst notes on Cerus Corporation are available to download free of charge at:
http://www.AnalystsReview.com/04092014/CERS/report.pdf
--
Galena Biopharma, Inc. Analyst Notes
On April 4, 2014, Galena Biopharma, Inc.'s (Gale Biopharma) stock declined 4.20%, closing at $2.28. The Company's stock went down by 10.94% over the past three-day trading period, compared to the Nasdaq Composite which dipped 3.29% during the same trading period. The full analyst notes on Galena Biopharma, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/GALE/report.pdf
--
ZELTIQ Aesthetics, Inc. Analyst Notes
On April 3, 2014, ZELTIQ Aesthetics, Inc. (ZELTIQ) reported that it has launched the CoolSmooth™ applicator, the latest addition to the successful CoolSculpting® range of applicators. ZELTIQ stated that CoolSmooth is the first and only non-surgical solution for reducing fat on the outer thighs, with a comfortable design that adjusts to fit each unique patient. According to the Company, when combined with CoolFit™ which is designed to treat the inner thigh, CoolSmooth now provides patients the opportunity to treat the entire thigh area. Commenting on the launch, Mark Foley, President and CEO of ZELTIQ, stated, "The introduction of the CoolSmooth applicator provides a new solution to individuals who struggle to reduce fat in the thigh area, a difficult-to-treat part of the body. Through our newest applicator, we are excited by the opportunity to expand our current offerings to physicians and, ultimately, the individuals who may benefit from our unique technology. Results achieved with CoolSmooth add to the growing body of evidence demonstrating the safety, efficacy and long-lasting results of the CoolSculpting procedure." The full analyst notes on ZELTIQ Aesthetics, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/ZLTQ/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article